The sales of the type 2 diabetes drug, Actos, have decreased after the reports were released that the drug has been linked to the increased risk of bladder cancer when taken for over a year.
The drug makers, Takeda Pharmaceuticals Co., has stated that they have net profit of $1.74 billion for the first part of the year, ending in September. The company has estimated that this number may fall up to 31 percent by March 2012 at the current rate.
The company is reporting that this is mainly due to the decreased sales of Actos. Since January, shares in Takeda have dropped nearly 13 percent. Actos used to be the company’s more profitable drug, but in September 2010, the FDA released early data from a study they were conducting on the use of Actos for an extended period of time. They found that those who used the drug for over a year saw an increased risk of developing bladder cancer.
If you or a loved one has used Actos and developed bladder cancer as a result, you need experienced representation on your side. Contact the Actos bladder cancer lawsuit lawyers of Williams Kherkher by calling 800-641-9810 today.